Mr. Donald McCaffrey reports

RESVERLOGIX ANNOUNCES DETAILS OF ANTICIPATED DISTRIBUTION OF NEWCO SHARES

Further to the previously announced plan of arrangement to spin out Resverlogix Corp.'s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp. (formerly 1741273 Alberta Ltd.), a newly incorporated company, the record date for the distribution of common shares of Newco is May 31, 2013. Upon completion of the arrangement, shareholders of Resverlogix will own one common share of Resverlogix and one Newco share for each common share of Resverlogix held immediately prior to the arrangement becoming effective.

The Toronto Stock Exchange has determined that its due-bills trading procedure will apply to the distribution of Newco shares pursuant to the arrangement. Trades of common shares of Resverlogix entered into from and including May 29, 2013, until June 3, 2013 (the anticipated effective date of the arrangement and the distribution payment date), will have a due bill attached, which will allow the purchaser of Resverlogix shares to receive the applicable distribution of Newco shares instead of the seller of Resverlogix shares, even if such trades are settled after the May 31, 2013, distribution record date.

Ex distribution trading of the Resverlogix shares will commence at the opening of the TSX on June 4, 2013. Investors who enter into trades to purchase Resverlogix shares on or after the ex distribution date of June 4, 2013, will not be entitled to the distribution. The due bills will be redeemed on June 6, 2013, once all trades with attached due bills entered into up to June 3, 2013, have settled.

The anticipated dates provided may change for a number of reasons, including inability to secure necessary shareholder, regulatory, court or other third party approvals in the time assumed or the need for additional time to satisfy the other conditions to the completion of the arrangement. Investors are encouraged to consult with their financial advisers regarding the specific implications of buying or selling Resverlogix shares before, on or after the anticipated effective date of the arrangement.

Pursuant to the arrangement, Resverlogix intends to retain its research and development activities related to the development of compounds for applications with indications involving a therapeutic increase in Apolipoprotein A-1, including the clinical program related to RVX-208, a first-in-class small molecule for the treatment of atherosclerosis, and it intends to spin off all other research and development activities related to its epigenetic platform technology to Newco. Pursuant to the arrangement, Newco will also be issued royalty preferred shares in the capital of Resverlogix, which will provide Newco with a dividend equal to 6 to 12 per cent of net Apo revenue as described in the circular. As part of the arrangement, Resverlogix will transfer to Newco all of the indebtedness of RVX Therapeutics owing to Resverlogix. Resverlogix will also transfer between $5-million and $10-million of cash to provide for the initial capitalization of Newco.

It is not anticipated that the Newco shares will be listed on any stock exchange upon completion of the arrangement, and therefore there will be no public market to trade the Newco shares. Resverlogix shareholders may therefore not be able to realize on the value of the Newco shares as the liquidity of the Newco shares will be limited until such time as the Newco shares are listed on a stock exchange. The board of directors of Resverlogix and the board of directors of Newco have determined not to seek a listing of the Newco shares on any stock exchange upon completion of the arrangement in view of the early stages of development of the spinoff assets. The board of directors of Newco will give due consideration in the future as to whether it is in the best interests of shareholders of Newco that the Newco shares be listed.

For further information regarding the arrangement, please see Resverlogix's information circular dated April 29, 2013, which has been sent to shareholders of Resverlogix, in connection with the special meeting to approve the arrangement. The information circular has also been filed on SEDAR.

We seek Safe Harbor.